10.24.06
Orion Teams with Mayo for Validation of Breast Cancer Detection
St. Louis-based Orion Genomics has announced a collaboration with the Mayo Clinic to establish the utility of using its breast cancer biomarkers in the early detection of other cancers, such as lung, ovarian, and colon cancers. Mayo will be used to “validate the tumor specificity of Orion’s breast cancer biomarkers by analyzing the cross reactivity of these epigenetic biomarkers in more than a dozen additional cancer types.” By screening breast cancer samples using Orion’s proprietary MethylScope platform, the company has identified over 50 novel biomarkers (a change in methylation pattern between breast cancer and control samples) to date. Link
No comments yet.